Healthcare -
Biotechnology - NASDAQ - CH
$ 19.92
2.14 %
$ 1.09 B
Market Cap
-6.79
P/E
1. INTRINSIC VALUE
Balance Sheet
Oculis Holding AG
| Current Assets | 105 M |
| Cash & Short-Term Investments | 98.7 M |
| Receivables | 777 K |
| Other Current Assets | 5.46 M |
| Non-Current Assets | 15.5 M |
| Long-Term Investments | 0 |
| PP&E | 1.69 M |
| Other Non-Current Assets | 13.8 M |
| Current Liabilities | 44.2 M |
| Accounts Payable | 5.87 M |
| Short-Term Debt | 315 K |
| Other Current Liabilities | 38 M |
| Non-Current Liabilities | 2.74 M |
| Long-Term Debt | 865 K |
| Other Non-Current Liabilities | 1.87 M |
EFFICIENCY
Earnings Waterfall
Oculis Holding AG
| Revenue | 883 K |
| Cost Of Revenue | 29.2 M |
| Gross Profit | -28.4 M |
| Operating Expenses | 52.4 M |
| Operating Income | -80.7 M |
| Other Expenses | 5.22 M |
| Net Income | -85.9 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Oculis Holding AG
| Net Income | -85.9 M |
| Depreciation & Amortization | 406 K |
| Capital Expenditures | -230 K |
| Stock-Based Compensation | 9.78 M |
| Change in Working Capital | 14.2 M |
| Others | 29.7 M |
| Free Cash Flow | -47.7 M |
Wall Street Analysts Price Targets
Oculis Holding AG
OCS has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
OCS does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Oculis Holding AG
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Oculis Publishes Results of 2025 Annual General Meeting
ZUG, Switzerland, June 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), today announced the results from its 2025 Annual General Meeting held on June 4, 2025 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:00 p.m. CEST / 9:00 a.m. EDT.
globenewswire.com
- 1 week ago
Oculis Publishes Results of 2025 Annual General Meeting
ZUG, Switzerland, June 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), today announced the results from its 2025 Annual General Meeting held on June 4, 2025 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:00 p.m. CEST / 9:00 a.m. EDT.
globenewswire.com
- 1 week ago
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
ZUG, Switzerland, June 03, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company.
globenewswire.com
- 2 weeks ago
Oculis to Participate in Upcoming June Investor Conferences
ZUG, Switzerland, June 03, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that Oculis will be participating in the following upcoming investor conferences:
globenewswire.com
- 2 weeks ago
Oculis to Participate in Upcoming June Investor Conferences
ZUG, Switzerland, June 03, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that Oculis will be participating in the following upcoming investor conferences:
globenewswire.com
- 2 weeks ago
Oculis Publishes Invitation to the Annual General Meeting
ZUG, Switzerland, May 09, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), today published the invitation to the 2025 Annual General Meeting, which will be held on June 4, 2025 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:00 p.m. CEST / 9:00 a.m. EDT.
globenewswire.com
- 1 month ago
Oculis Publishes Invitation to the Annual General Meeting
ZUG, Switzerland, May 09, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), today published the invitation to the 2025 Annual General Meeting, which will be held on June 4, 2025 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:00 p.m. CEST / 9:00 a.m. EDT.
globenewswire.com
- 1 month ago
Oculis Holding AG (OCS) Reports Q1 Loss, Tops Revenue Estimates
Oculis Holding AG (OCS) came out with a quarterly loss of $0.77 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $0.44 per share a year ago.
zacks.com
- 1 month ago
Oculis Reports Q1 2025 Financial Results and Provides Company Update
The recent R&D Day ( replay ) showcased material progress across all three core assets and highlighted potential first-in-class neuroprotection treatment in neuro-ophthalmology, an area of high unmet medical need, thanks to Privosegtor's (OCS-05) positive results from the ACUITY trial in Acute Optic Neuritis OCS-01: DIAMOND Ph3 trials enrollment completed with over 800 patients randomized; topline results expected Q2 2026 for the first potential eye drop treatment for diabetic macular edema (DME) Licaminlimab (OCS-02) genotype-based development plan to drive a personalized medicine approach in dry eye disease (DED) aligned with FDA; first registrational trial initiation anticipated in 2H 2025 Cash, cash equivalents and short-term investments of $206.3 million as of March 31, 2025, reflects proceeds from the $100.0 million financing in February 2025, providing cash runway into early 2028 ZUG, Switzerland, May 08, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced results for the first quarter ended March 31, 2025 and provided an overview of the Company's progress. Riad Sherif M.D.
globenewswire.com
- 1 month ago
Oculis Reports Q1 Financial Results and Provides Company Update
ZUG, Switzerland, May 08, 2025 (GLOBE NEWSWIRE) -- The recent R&D Day ( replay ) showcased material progress across all three core assets and highlighted potential first-in-class neuroprotection treatment in neuro-ophthalmology, an area of high unmet medical need, thanks to Privosegtor's (OCS-05) positive results from the ACUITY trial in Acute Optic Neuritis OCS-01: DIAMOND Ph3 trials enrollment completed with over 800 patients randomized; topline results expected Q2 2026 for the first potential eye drop treatment for diabetic macular edema (DME) Licaminlimab (OCS-02) genotype-based development plan to drive a personalized medicine approach in dry eye disease (DED) aligned with FDA; first registrational trial initiation anticipated in 2H 2025 Cash, cash equivalents and short-term investments of $206.3 million as of March 31, 2025, reflects proceeds from the $100.0 million financing in February 2025, providing cash runway into early 2028 Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced results for the first quarter ended March 31, 2025 and provided an overview of the Company's progress. Riad Sherif M.D.
globenewswire.com
- 1 month ago
Earnings Preview: Oculis Holding AG (OCS) Q1 Earnings Expected to Decline
Oculis Holding AG (OCS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zacks.com
- 1 month ago
Oculis to Present at Upcoming May Investor Conferences
ZUG, Switzerland, May 07, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that Oculis will be attending and presenting at the following upcoming investor conferences:
globenewswire.com
- 1 month ago
8. Profile
Summary
Oculis Holding AG OCS
COUNTRY
CH
INDUSTRY
Biotechnology
MARKET CAP
$ 1.09 B
Dividend Yield
0.00%
Description
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.
Contact
Bahnhofstrasse 7, Zug, 6300
https://oculis.com
IPO
Date
May 18, 2021
Employees
49
Officers
Ms. Rebecca Weil
Chief Commercial Officer
Dr. Sharon Klier M.D., M.P.H.
Chief Development Officer
Dr. Snehal Shah Pharm.D.
President of Research & Development
Ms. Sylvia Cheung
Chief Financial Officer
Ms. Gudrun Bachmann Ph.D.
Chief Technology Officer
Ms. Virginia R. Dean
Chief Human Resources Officer
Mr. Daniel S. Char J.D.
Chief Legal Officer
Dr. Riad Sherif M.B.A., M.D.
Chief Executive Officer & Director
Mr. Páll Ragnar Jóhannesson
Chief Business Officer
Dr. Ramin Tadayoni M.D., Ph.D.
Chief Scientific Officer